Global Clinical Chemistry Analyzers Market Size, Share, Trends & Growth Forecast Report By Product, Test Type, End-User and Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Industry Analysis From 2025 To 2033.

Updated On: June, 2024
ID: 12995
Pages: 150

Global Clinical Chemistry Analyzers Market Size

The size of the global clinical chemistry analyzers market was worth USD 14.75 billion in 2024. The global market is anticipated to grow at a CAGR of 6.44% from 2025 to 2033 and be worth USD 25.87 billion by 2033 from USD 15.7 billion in 2025. 

The global clinical chemistry analyzers market is estimated to hit USD 25.87 billion by 2033.

MARKET DRIVERS

Technological advancements play an essential role in transforming the clinical chemistry analyzer market.

Automation in the Clinical chemistry analyzers has improved the testing volumes and efficiency and minimized human errors. Erba XL 640 is a fully automated random-access clinical chemistry analyzer with an autoloader. This equipment helps in establishing better workflow and helps in achieving faster TAT. Furthermore, strengthening favorable reimbursement policies and technologies to develop flexible instruments is possible for the key players by adopting automated chemistry analyzers.

The evolution of technology, rising R&D activities, and integration of advanced software technologies are expected to shape the market in the future.

Next-generation clinical chemistry analyzers will improve hospital workflow, point-of-care diagnostics centers, and laboratories. Technical innovations such as next-generation microfluidic devices can efficiently separate CTCs from whole blood. Implementing favorable government initiatives, schemes, and funding to develop diagnostics is expected to have various opportunities for the market.

Y-O-Y growth in the aging population significantly boosts the clinical chemistry analyzers market.

Due to age-related diseases such as diabetes, hypertension, cardiovascular, liver, and other diseases in senior people, the market is expected to increase significantly. According to United Nations, 703 million people aged 64 and above in 2019. As per the United States Census Bureau’s Statistics, the number of elderly populations is expected to increase by 19 million between 2020-2030. Furthermore, the number of people aged above 85 will likely triple from an estimated 6 million to about 24 million by 2060. Such a rise in the geriatric population will boost the market forward.

MARKET RESTRAINTS

The high cost of analyzers is a significant restraint to the growth of the clinical chemistry analyzers market. Laboratories cannot afford high-cost instruments. In addition, the shortage of skilled technicians and the gap between the supply and demand of pathologists and technicians are significant challenges to market growth.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2024 to 2033

Base Year

2024

Forecast Period

2025 to 2033

CAGR

6.44%

Segments Covered

By Test Type, Product Type, End-User, and Region.

 

Various Analyses Covered

Global, Regional, and country-level analysis; Segment-Level Analysis, DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

 

Market Leaders Profiled

Abbott Laboratories, Beckman Coulter Inc., Biobase Biodusty (Shandong), Co., Ltd., Dirui Industrial Co., Ltd., EKF Diagnostics, ELITechGroup, Erba Mannheim, F. Hoffmann-La Roche Ltd., Genrui Biotech Inc., Hitachi High-Tech Corporation, Horiba, Ltd, Thermo Fisher Scientific and KPM Analytics, Inc., and Others.

 

 

SEGMENTAL ANALYSIS

By Test Type Insights

The basic metabolic panel segment dominated the clinical chemistry analyzers market in 2024.

The basic metabolic panel had the largest share of the clinical chemistry analyzers market in 2024. It gains significant demand for newborn screening, which allows early detection of congenital genetic and metabolic disorders. Rising importance, awareness of point-of-care testing, and the growing prevalence of lifestyle-induced diseases are the key drivers of the market. Basic metabolic panels provide clinical information regarding the issues caused by a chemical imbalance.

By Product Type Insights

Based on the product type, the reagents segment led the market in 2024, owing to the vast array of reagents present in the market. Reagents must be the highest-efficiencies, have optimum sensitivity, and ensure minimized performance variation.

By End-User Insights

Based on the end-user, the hospital segment accounted for the most significant share of the market in 2024, owing to the frequent readmission and large sample volumes. Additionally, favorable infrastructure facilitates and increasing government initiatives are favoring this segment to register better share among other end-user types.

REGIONAL ANALYSIS

In 2024, North America accounted for the highest share of the clinical chemistry analyzers market.

Geographically, North America dominated the market for clinical chemistry analyzers worldwide in 2024. This region's demand for clinical chemistry analyzers is expected to remain high due to the need for routine diagnostic procedures. In addition, the rising prevalence of cancer and diabetes, an aging population, and increasing awareness are majorly putting this region first, accounting for a leading share of the global market among other regions. Furthermore, one of the major market players, Siemens Healthineers, announced the global commercial availability of its Atellica Solution automation-ready immunoassay and chemistry analyzers. DynLife healthcare facility in Canada was the first to adopt this solution. Thus, North America is expected to hold the largest share of the global clinical chemistry analyzers market during the forecast period.

The Asia Pacific is predicted to register the fastest CAGR during the forecast period. Among all, China had the highest share of the APAC market in 2024. A China-based player, Snibe, has launched the new Bioassays C8 automatic biochemistry analyzer. It is used for powerful performance and scalability. Rapid urbanization, the launch of innovative products in the region, and the adoption of a sedentary lifestyle are the factors driving the region forward.

Europe's steady growth accounted for a substantial share of the global clinical chemistry analyzers market in 2024. Small and medium laboratories are expected to drive the European market.

Due to improving healthcare infrastructure and expanding distribution network clinical chemistry analyzer market in Latin America is expected to grow during the forecast period.

TOP COMPANIES IN THIS MARKET

Companies playing a significant role in the global clinical chemistry analyzers market profiled in this report are Abbott Laboratories, Beckman Coulter Inc., Biobase Biodusty (Shandong), Co., Ltd., Dirui Industrial Co., Ltd., EKF Diagnostics, ELITechGroup, Erba Mannheim, F. Hoffmann-La Roche Ltd., Genrui Biotech Inc., Hitachi High-Tech Corporation, Horiba, Ltd, Thermo Fisher Scientific and KPM Analytics, Inc.

RECENT HAPPENINGS IN THIS MARKET

  • In January 2020, Sysmex invested in Astrego Diagnostics to develop new urinalysis solutions for the primary care business.
  • In April 2019, NexTech AR Solutions announced an agreement with Block Scientific, a primary provider of clinical laboratory equipment, to supply 3D product models through its AR eCommerce platform.

MARKET SEGMENTATION

This global clinical chemistry analyzers market research report is segmented and sub-segmented into the following categories.

By Test Type

  • Basic Metabolic Panels
  • Electrolyte Panels
  • Liver Panels
  • Lipid Profiles
  • Renal Panels
  • Thyroid Function Panels
  • Specialty Chemical Tests

By Product Type

  • Analyzers
  • Reagents

By End-User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Research Laboratories & Institutes

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Please wait. . . . Your request is being processed

Anil Kumar P is research manager at Market Data Forecast and responsible for Healthcare Domain.

Author

Anil Kumar P (Research Manager - Healthcare)

Anil Kumar P is the lead author of this report and the manager of the team responsible for authoring healthcare reports at Market Data Forecast. He holds a Bachelor’s degree in Pharmacy (Hons.) from BITS Pilani, one of India’s premier institutions. Over the past seven years, Anil has gained extensive experience working with multiple market research companies, where he has collaborated with a diverse range of clients—from innovative startups to Fortune 500 companies—delivering data-driven insights and strategic advice that drive business growth.

Read More

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample